3.000SEK-2.91%Mkt Cap: 400.61M SEKP/E: —Last update: 2026-06-01
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, wh…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap400.61M SEK
Enterprise Value358.83M SEK
Revenue (TTM)—
Gross Profit0 SEK
Net Income (TTM)-76.25M SEK
Revenue/Share—
Last Price3.000 SEK
Fiscal Year EndDec 2019
MR QuarterMar 2026
Employees—
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-25.75
PEG—
EV/EBITDA-5.06
EV/Revenue—
P/S—
P/B4.72
EPS (TTM)-0.57
EPS (Forward)-0.12
52W Range
2.53017% of range5.230
52W High5.230 SEK
52W Low2.530 SEK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-76.66%
ROA-68.12%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-72.25M SEK
CapEx (TTM)57.00K SEK
FCF Margin—
FCF Yield-15.68%
Net Debt-33.20M SEK
Net Debt/EBITDA0.47
Balance Sheet
Debt/Equity0.01
Current Ratio2.81
Quick Ratio2.70
Book Value/Sh0.6540 SEK
Cash/Share0.2670 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)5.600 SEK
Target Range3.700 SEK – 8.500 SEK
# Analysts4
Ownership
Shares Out.133.54M
Float117.54M
Insiders15.83%
Institutions20.74%
Technical
SMA 503.011 (-0.4%)
SMA 2003.169 (-5.3%)
Beta0.89
S&P 52W Chg27.70%
Avg Vol (30d)707.03K
Avg Vol (10d)878.85K
Technical Indicators
RSI (14)52.6
MACD0.0357
MACD Signal0.0076
MACD Hist.+0.0280
BB Upper3.256 SEK
BB Middle3.002 SEK
BB Lower2.748 SEK
BB Width16.92%
ATR (14)0.1721 SEK
Vol Ratio (20d)0.85x